• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙型肝炎病毒NS3和核心蛋白混杂CD4 + T细胞表位的天然供体中T细胞启动的差异能力。

Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins.

作者信息

Castelli Florence A, Leleu Mélanie, Pouvelle-Moratille Sandra, Farci Sandrine, Zarour Hassane M, Andrieu Muriel, Auriault Claude, Ménez André, Georges Bertrand, Maillere Bernard

机构信息

CEA, iBiTecS, Service d'Ingénierie Moléculaire des Protéines, Gif Sur Yvette, France.

出版信息

Eur J Immunol. 2007 Jun;37(6):1513-23. doi: 10.1002/eji.200636783.

DOI:10.1002/eji.200636783
PMID:17492804
Abstract

To understand the inter-individual and virus-independent variability of CD4+ T cell responses to HCV components, we evaluated the effect on these responses of HLA II molecules in uninfected healthy donors. Using HLA II-specific binding assays, we identified, in the Core and NS3 proteins, 21 long fragments and 24 15-mer peptides that bound to four to eight of the most preponderant HLA II molecules. We then evaluated the priming capacity of eight long promiscuous peptides in 12 HLA-unrelated healthy donors. The NS3 1250-1264 peptide primed T cells in all the naive donors, while five others were stimulating in at least half of the individuals. We also report sequences that bind to multiple HLA II molecules but are weakly immunogenic. We therefore conclude that (i) broad HLA II specificity is only a prerequisite for a peptide to be stimulating in multiple individuals, and (ii) promiscuous peptides widely differ in their capacity to prime CD4+ T cells from uninfected healthy donors. We suggest that these priming differences result from inter-individual variations in the peptide-specific T cell repertoire. Interestingly, five of the most immunogenic peptides we identified correspond to frequently targeted T cell epitopes in infected patients.

摘要

为了解未感染健康供体中CD4+ T细胞对丙型肝炎病毒(HCV)成分反应的个体间及病毒非依赖性变异性,我们评估了HLA II类分子对这些反应的影响。通过HLA II类特异性结合试验,我们在核心蛋白和NS3蛋白中鉴定出21个长片段和24个15肽,它们与四种至八种最主要的HLA II类分子结合。然后我们评估了八个长混杂肽在12名HLA不相关健康供体中的启动能力。NS3 1250-1264肽在所有未接触过抗原的供体中启动T细胞,而其他五种肽在至少一半个体中具有刺激作用。我们还报告了与多种HLA II类分子结合但免疫原性较弱的序列。因此,我们得出结论:(i)广泛的HLA II类特异性只是一种肽在多个个体中具有刺激作用的前提条件,(ii)混杂肽在启动未感染健康供体的CD4+ T细胞的能力上差异很大。我们认为这些启动差异是由肽特异性T细胞库的个体间变异导致的。有趣的是,我们鉴定出的五种免疫原性最强的肽对应于感染患者中经常靶向的T细胞表位。

相似文献

1
Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins.丙型肝炎病毒NS3和核心蛋白混杂CD4 + T细胞表位的天然供体中T细胞启动的差异能力。
Eur J Immunol. 2007 Jun;37(6):1513-23. doi: 10.1002/eji.200636783.
2
Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively.对HIV反式激活蛋白(Tat)和病毒蛋白R(Vpr)的CD4 + T细胞反应的免疫流行率分别由聚集表位和分散表位提供。
Eur J Immunol. 2008 Oct;38(10):2821-31. doi: 10.1002/eji.200738072.
3
Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins.丙型肝炎病毒NS3和NS4蛋白内免疫显性CD4 + T细胞表位的最小T细胞刺激序列及HLA限制谱
J Virol. 2005 Oct;79(19):12425-33. doi: 10.1128/JVI.79.19.12425-12433.2005.
4
Longitudinal mapping of protective CD4+ T cell responses against HCV: analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes.针对丙型肝炎病毒的保护性CD4 + T细胞应答的纵向图谱分析:波动的显性和隐性HLA-DR11限制性表位分析
J Viral Hepat. 2004 Jul;11(4):324-31. doi: 10.1111/j.1365-2893.2004.00516.x.
5
In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R.体外人CD4 + T细胞对痘苗保护性抗原B5R和A33R的反应。
Mol Immunol. 2009 Apr;46(7):1481-7. doi: 10.1016/j.molimm.2008.12.016. Epub 2009 Feb 3.
6
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.NY-ESO-1编码被黑色素瘤反应性CD4 + T细胞识别的DRB1*0401限制性表位。
Cancer Res. 2000 Sep 1;60(17):4946-52.
7
Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.通过用编码具有II类相关恒定链肽基因交换的恒定链的信使核糖核酸进行电穿孔的树突状细胞有效呈递已知的HLA II类限制性MAGE-A3表位。
Cancer Res. 2003 Sep 1;63(17):5587-94.
8
In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.负载含胆固醇疏水化支链淀粉与NY-ESO-1蛋白复合物的树突状细胞对CD8和CD4 T细胞的体外刺激:一种新的HLA-DR15结合CD4 T细胞表位的鉴定
Clin Cancer Res. 2006 Mar 15;12(6):1921-7. doi: 10.1158/1078-0432.CCR-05-1900.
9
The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.LAGE-1的可变开放阅读框产生了多个混杂的、受HLA-DR限制的表位,这些表位可被辅助性T细胞1型肿瘤反应性CD4 + T细胞识别。
Cancer Res. 2003 Oct 1;63(19):6506-15.
10
Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients.从B亚型HIV-1全基因组中鉴定新型共有CD4 T细胞表位,这些表位常被HIV-1感染患者识别。
AIDS. 2006 Nov 28;20(18):2263-73. doi: 10.1097/01.aids.0000253353.48331.5f.

引用本文的文献

1
Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity.治疗性抗体被内吞进入树突状细胞是其产生免疫原性的一个风险因素。
Front Immunol. 2024 Aug 28;15:1406643. doi: 10.3389/fimmu.2024.1406643. eCollection 2024.
2
SILVI, an open-source pipeline for T-cell epitope selection.SILVI,一种用于 T 细胞表位选择的开源管道。
PLoS One. 2022 Sep 7;17(9):e0273494. doi: 10.1371/journal.pone.0273494. eCollection 2022.
3
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays.
临床前免疫原性风险评估中的分析方法多样性:实现抗原性分析方法的潜在协调化。
MAbs. 2022 Jan-Dec;14(1):1993522. doi: 10.1080/19420862.2021.1993522.
4
Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs.在注射吸毒人群中丙型肝炎病毒的宿主内进化动态。
Sci Rep. 2021 May 11;11(1):9986. doi: 10.1038/s41598-021-88132-8.
5
Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses.将非天然氨基酸引入 T 细胞表位以减轻肽特异性 T 细胞反应。
Front Immunol. 2021 Mar 11;12:637963. doi: 10.3389/fimmu.2021.637963. eCollection 2021.
6
Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.设计包含免疫原性利什曼原虫蛋白的 HLA Ⅰ类和Ⅱ类限制性表位的多表位肽,并评估治愈的皮肤利什曼病患者中诱导的 CD4+和 CD8+ T 细胞反应。
PLoS Negl Trop Dis. 2020 Mar 16;14(3):e0008093. doi: 10.1371/journal.pntd.0008093. eCollection 2020 Mar.
7
Heterologous Immunity between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens.腺病毒与丙型肝炎病毒(HCV)之间的异源免疫:含有来自无关病原体抗原的重组腺病毒疫苗载体诱导针对 HCV 抗原的交叉反应性免疫。
Cells. 2019 May 26;8(5):507. doi: 10.3390/cells8050507.
8
Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension.围绕丙型肝炎病毒免疫的未解之谜:异源免疫增添了新的维度。
Int J Mol Sci. 2017 Jul 27;18(8):1626. doi: 10.3390/ijms18081626.
9
Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors.从健康供体中鉴定出的英夫利昔单抗和利妥昔单抗的CD4 T细胞表位的特性分析
Front Immunol. 2017 May 5;8:500. doi: 10.3389/fimmu.2017.00500. eCollection 2017.
10
Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.鉴定和回顾性验证丙型肝炎病毒 4 型蛋白组中的 T 细胞表位:一种加速表位驱动疫苗开发的方法。
Hum Vaccin Immunother. 2014;10(8):2366-77. doi: 10.4161/hv.29177.